FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the pricing of its upsized initial public offering of 3,750,000 shares of its common stock at an initial public offering price of $12.00 per share.

弗吉尼亚州福尔斯彻奇，2026年10月8日（环球电讯社）——临床阶段生物制药公司Retension Pharmaceuticals, Inc.（纳斯达克股票代码：RTSN）（以下简称“Retension”或“公司”），专注于开发用于治疗高血压及其他心血管疾病药物，今日宣布其扩大后的首次公开发行（IPO）定价，以每股12.00美元的价格发行375万股普通股。

The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million. All shares of common stock are being offered by Retension. Retension has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

在扣除由 Retension 支付的承销折扣、佣金及其他发行费用之前，Retension 从本次发行中获得的总收益预计为 4,500 万美元。所有普通股股份均由 Retension 发行。Retension 已授予承销商一项为期 30 天的选择权，可按首次公开发行价格减去承销折扣和佣金的价格，额外购买最多 562,500 股其普通股。

The offering is expected to close on or about October 13, 2026, subject to the satisfaction of customary closing conditions. The shares are expected to begin trading on October 9, 2026 on the Nasdaq Capital Market under the ticker symbol “RTSN.”.

本次发行预计将于2026年10月13日或左右完成，前提是满足惯常的交割条件。股票预计将于2026年10月9日在纳斯达克资本市场开始交易，股票代码为“RTSN”。

Retension intends to use the net proceeds from the offering, together with existing cash and cash equivalents, to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension (uHTN) and to prepare for, support and advance the planned Phase 3 clinical trial of RTN-001 in uHTN, with the remainder to be used for general corporate purposes and other operating expenses..

Retension 计划将本次发行的净收益，连同现有现金及现金等价物，用于完成 RTN-001 在治疗未控制高血压（uHTN）方面的 2b 期临床试验，并为 RTN-001 在治疗 uHTN 方面计划的 3 期临床试验做准备、提供支持并推动其进展，剩余资金将用于一般公司用途及其他运营支出。

Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Titan Partners is acting as lead manager for the offering.

Leerink Partners、Guggenheim Securities 和 Oppenheimer & Co. 担任本次发行的联席账簿管理人。Titan Partners 担任本次发行的主承销商。

Registration statements relating to these securities became effective on October 8, 2026. The offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext.

与这些证券相关的注册声明已于2026年10月8日生效。本次发行仅通过招股说明书进行。在最终招股说明书可供获取时，可通过电话 (800) 808-7525 转分机号，向 Leerink Partners LLC（收件人：辛迪加部门，地址：马萨诸塞州波士顿市 State Street 53号40层，邮编02109）索取与本次发行相关的最终招股说明书副本。

6105 or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimsecurities.com..

6105，或通过电子邮件发送至 syndicate@leerink.com；或致函 Guggenheim Securities, LLC，收件人：股票承销部，地址：330 Madison Ave., 8th Floor, New York, NY 10017，电话：(212) 518-9544，或通过电子邮件发送至 GSEquityProspectusDelivery@guggenheimsecurities.com。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售这些证券的要约，也不构成购买这些证券的要约的招揽；在任何州或其他司法管辖区，若此类要约、招揽或销售在根据该州或其他司法管辖区的证券法进行注册或资格认定之前属于违法行为，则不得在该等地出售这些证券。

About Retension Pharmaceuticals

关于 Retension Pharmaceuticals

Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company’s lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.

Retension Pharmaceuticals 是一家临床阶段的生物制药公司，专注于开发用于治疗高血压及其他心血管疾病的药物。公司的主要临床候选药物 RTN-001 正在针对难治性和控制不佳的高血压患者进行开发。

About RTN-001

关于 RTN-001

Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor designed to enhance nitric oxide signaling in central arteries not adequately reached by first-generation PDE5 inhibitors, thereby addressing a core driver of hypertension. RTN-001 has been studied in multiple clinical trials totaling 265 enrolled subjects.

Retension Pharmaceuticals 正在开发 RTN-001，这是一种靶向心血管的下一代 PDE5 抑制剂，旨在增强第一代 PDE5 抑制剂未能充分作用的中枢动脉中的一氧化氮信号传导，从而解决高血压的一个核心驱动因素。RTN-001 已在多项临床试验中进行了研究，总计入组受试者 265 名。

In two Phase 2 pilot trials, RTN-001 has achieved clinically meaningful placebo-adjusted reductions in systolic blood pressure and diastolic blood pressure in patients with hypertension. A Phase 2b trial of RTN-001 in hypertension is ongoing. RTN-001 is being developed under an exclusive worldwide license from Sanofi S.A..

在两项二期试点试验中，RTN-001 在高血压患者中实现了具有临床意义的、经安慰剂校正的收缩压和舒张压降低。目前，RTN-001 针对高血压的二期 b 类试验正在进行中。RTN-001 的开发基于从赛诺菲公司（Sanofi S.A.）获得的独家全球许可。

Special Note Regarding Forward-Looking Statements

关于前瞻性陈述的特别说明

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to the Company’s closing of its initial public offering. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control.

本新闻稿包含1995年《私人证券诉讼改革法》“安全港”条款所定义的“前瞻性陈述”，包括但不限于公司完成其首次公开募股。前瞻性陈述受多种风险和不确定性的影响，其中许多涉及超出公司控制范围的因素或情况。

All statements other than statements of historical fact, including statements regarding Retension’s initial public offering, future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on Retension’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, therefore you should not place undue reliance on these forward-looking statements.

除历史事实陈述外，所有陈述，包括有关Retension首次公开发行、未来经营业绩或财务状况、业务战略与计划以及管理层对未来经营目标的陈述，均为前瞻性陈述。这些前瞻性陈述基于Retension对当前未来事件的预期和假设，而此类事件本质上受制于难以预测的不确定性、风险和情况变化，因此您不应过度依赖这些前瞻性陈述。

Words, including but not limited to, “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.

包括“预期”、“预计”、“应”、“相信”、“希望”、“目标”、“规划”、“目的”、“估计”、“潜在”、“预测”、“可能”、“将”、“或许”、“可以”、“打算”、“应当”等词语，以及这些词语的变体、否定形式或类似表达，旨在识别这些前瞻性陈述。

Retension’s actual results may differ materially from those expressed in, or implied by, such forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) on September 18, 2026 as well as other documents that may be filed by the Company from time to time with the SEC.

由于多种因素，Retension 的实际结果可能与该等前瞻性陈述中明示或暗示的结果存在重大差异，这些因素包括但不限于公司于2026年9月18日向美国证券交易委员会（“SEC”）提交的S-1表格注册声明中详述的风险，以及公司可能不时向SEC提交的其他文件中所述的风险。

Additional.

附加的。

www.sec.gov

www.sec.gov

. Retension undertakes no obligation to update any forward-looking statements after the date of this press release or to conform such statements to actual results or revised expectations, except as required by law.

Retension 不承担在本新闻稿发布之日后更新任何前瞻性陈述或使此类陈述与实际结果或修订后的预期保持一致的义务，除非法律另有要求。

Contact:

联系方式：

Press and Investor Contact

媒体与投资者联系

Alex Schwartz

亚历克斯·施瓦茨

Chief Financial Officer

首席财务官

investors@retensionpharmaceuticals.com

investors@retensionpharmaceuticals.com